ScripTeva and Sanofi unveiled positive Phase IIb data on 17 December for the TL1A-targeting antibody candidate they are developing to compete against candidates from the same class at Roche and Merck &
ScripIn its latest effort to identify drugs with price increases that had the biggest impact on US health care spending, the Institute for Clinical and Economic Review (ICER) included Merck & Co.’s Key
Generics BulletinTeva is divesting Teva Takeda, its joint venture with Takeda Pharmaceutical in Japan, as it seeks to focus on bringing innovative medicines to the Japanese market. The JV will be acquired by JKI Co.,
ScripLife sciences venture capital major Abingworth is reportedly looking to raise up to $1.5bn in funding to be deployed for clinical development projects partnered with pharma companies in return for fut